Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02054481 · ClinicalTrials.gov registry record · Phase 2
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
A Phase 2 study of Psoriasis, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
- 20
- Study locations
NCT02054481 is a Phase 2 study of Psoriasis that has completed, run by Boehringer Ingelheim. The registered enrollment target is 166 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02054481, a Phase 2 study of Psoriasis, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG BI 655066
Study Locations (20)
Other
- 1311.2.35802 Boehringer Ingelheim Investigational Site - Helsinki
- 1311.2.35801 Boehringer Ingelheim Investigational Site - Turku
- 1311.2.33005 Boehringer Ingelheim Investigational Site - Marseille
- 1311.2.33002 Boehringer Ingelheim Investigational Site - Nice
Ontario
- 1311.2.20002 Boehringer Ingelheim Investigational Site - Markham
- 1311.2.20005 Boehringer Ingelheim Investigational Site - Peterborough
- 1311.2.20003 Boehringer Ingelheim Investigational Site - Waterloo
New Jersey
- 1311.2.10001 Boehringer Ingelheim Investigational Site - East Windsor
- 1311.2.10009 Boehringer Ingelheim Investigational Site - Verona
Texas
- 1311.2.10006 Boehringer Ingelheim Investigational Site - Dallas
- 1311.2.10011 Boehringer Ingelheim Investigational Site - Houston
California
- 1311.2.10010 Boehringer Ingelheim Investigational Site - Los Angeles
Florida
- 1311.2.10013 Boehringer Ingelheim Investigational Site - Port Orange
Illinois
- 1311.2.10003 Boehringer Ingelheim Investigational Site - Arlington Hts
Michigan
- 1311.2.10002 Boehringer Ingelheim Investigational Site - Bay City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02054481
The ClinicalTrials.gov registry entry for NCT02054481 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (66% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT02054481 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Ontario, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02054481 about?
NCT02054481 is a clinical study titled "BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab". The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.
What is the current status of trial NCT02054481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2014-02. Estimated completion is 2015-07.
What conditions does trial NCT02054481 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02054481?
The interventions under investigation include: Ustekinumab (DRUG), BI 655066 (DRUG).
Who is sponsoring clinical trial NCT02054481?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02054481 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.